• Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Home
  • About Us
  • Blog
  • Subscribe to the Journal
  • Contact Us
Sleep Diagnosis and Therapy

Sleep Diagnosis and Therapy

Official Publication of the American Sleep and Breathing Academy

A Pill for Sleep Apnea? A Pennsylvania-Based Pharma Company is Working on It

May 9, 2014 by admin

 

The Philadelphia Business Journal is reporting that Philadelphia-based Galleon Pharmaceuticals is working on a pill to treat sleep apnea.

 

The report reveals that James C. Mannion, founder and CEO of the 9-year-old Horsham biopharmaceutical company, is in the process of raising $20 million to support clinical testing of its two lead products: GAL-160, an oral medicine for sleep apnea and GAL-021, an intravenous drug being developed to treat respiratory complications in hospitalized patients receiving anesthetics and opioids for pain relief.

 

“The company has raised about $50 million from investors including venture-capital firms TPG Biotech, Morgenthaler Ventures and Healthcare Ventures,” George writes. “In 2005 Galleon received $500,000 in seed funding from BioAdvance, operator of the Biotechnology Greenhouse of Southeastern Pennsylvania. While potential applications for Galleon’s technology and compounds cover a range of breathing control disorders, Mannion said he will typically provide a more brief description of the company when meeting with potential investors.”

 

“I tell them we are developing a pill for sleep apnea,” said Mannion in The Journal. “Many people can relate to sleep apnea. Usually when I am in a room talking to people about the company, there is somebody who has it or whose brother, cousin, uncle or spouse has sleep apnea. They all say the same thing: People with sleep apnea hate wearing the mask.”

 

Mannion told George that to the best of his knowledge, no big pharma companies are working on a pill to treat sleep apnea. He noted the company combines elements of respiratory medicine and neurology in their research. “Most of the big pharmaceutical companies work in one area, but not both,” he said. “If they do both, (the researchers) usually work separately. We don’t have those silos.”

 

Source: Philadelphia Business Journal

Filed Under: Articles, Blog

Primary Sidebar

More to See

Snoring, American Sleep and Breathing Academy and the NY Times

August 23, 2022 By admin

Jazz Pharma Presents 17 New Posters for SLEEP 2022

June 6, 2022 By admin

Tags

apnea CPAP Health Home Sleep Home Sleep Testing insomnia narcolepsy obstructive sleep apnea Sleep sleep apnea sleep apnea symptoms sleep apnea syndrome sleep apnea treatment sleep appliances sleep buisness Sleep Business sleep center Sleep Centers sleep community sleep diagnosis sleep diagnostic sleep diagnostics sleep disease sleep disorder sleep disorder center sleep disordered breathing sleep disorders sleep heart health sleep industry sleeping Sleep Lab sleep labs sleep management sleep medicine sleep monitor sleep physicians sleep problems sleep studies sleep study sleep technologist sleep test sleep testing Technology therapy Treatment

Footer

About SleepDT

SleepDT Sleep Diagnosis and Therapy is a clinical Journal for allied Sleep Professionals, Neurologists, Psychiatrists, Pulmonologists, Primary Care Physicians, and other medical specialists. We also advocate on behalf of patient care in the field of Sleep Medicine

Recent

  • SUPPORT AND PROMOTE DENTAL SLEEP MEDICINE IN 2023!
  • Snoring, American Sleep and Breathing Academy and the NY Times
  • Jazz Pharma Presents 17 New Posters for SLEEP 2022
  • AJMC Hypes SLEEP 2022
  • Avadel Pharmaceuticals’ Stock Falls

NAVIGATION

  • Home
  • About Us
  • Blog
  • Subscribe to the Journal
  • Contact Us

Copyright © 2023 · Sleep Diagnosis and Therapy